Novartis, Astellas Intend To Disprove Eczema Treatments’ Cancer Risk

Novartis and Astellas aim to use ongoing studies to convince FDA to remove a requirement for a "black box" warning of potential cancer risk in labeling for their topical calcineurin inhibitors

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet